# Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

> **NCT06228560** · PHASE2 · COMPLETED · sponsor: **Longbio Pharma** · enrollment: 202 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **BIOLOGICAL:** LP-003
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Omalizumab

## Key facts

- **NCT ID:** NCT06228560
- **Lead sponsor:** Longbio Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-26
- **Primary completion:** 2025-04-17
- **Final completion:** 2025-11-14
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06228560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06228560, "Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06228560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*